

Special Issue

Technologies for the Development of Next Generation Adjuvanted Vaccines

Message from the Guest Editor

In the age of subunit vaccine platforms, the advancement of new technologies that can generate a potent immune response while retaining a good safety profile is a pre-requisite for the development of next generation vaccines. Vaccine adjuvants can be a powerful tool in new vaccine development, both for established and for emerging pathogens, enabling us to address issues such as subpopulations with impaired immune responses, or the need for vaccine dose-sparing. However, it is becoming increasingly clear that in the future, most advantageous vaccine formulations will need to combine both qualities: optimal cell targeting for vaccine uptake and the appropriate stimulation of the immune system to induce a lasting and effective response. This Special Issue focuses on novel technologies addressing vaccines and adjuvant formulation and delivery, the use of advanced (multicomponent) adjuvants, controlled antigen release approaches and the routes of administration. It also includes process development for the scaling up of manufacturing, and the considerations of the key attributes of vaccine development in a pandemic scenario.

Guest Editor

Dr. Anita Milicic

Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Old Road Campus Research Building, Headington OX3 7DQ, UK

Deadline for manuscript submissions

closed (28 February 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/50407

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).